Q-omics provides the consensus-scored IQSEC3 profile across patient tissues and cancer cell-line models. IQSEC3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IQSEC3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, IQSEC3 RNA expression shows 19,676 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where IQSEC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQSEC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQSEC3 survival associations across molecular data types. IQSEC3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQSEC3 RNA expression–survival associations across cancer types. High IQSEC3 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, SCLC, SKCM, HNSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IQSEC3 RNA expression.
This table summarizes IQSEC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IQSEC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQSEC3 shows lower tumor expression in KIRP, LUSC, LUAD, UCEC, KICH and BRCA. The KIRP box plot shows higher IQSEC3 RNA expression in normal versus tumor tissue (log2 FC = −1.433, t-test p < 0.001).
This table shows molecular features associated with IQSEC3 in patient tissues and cancer cell lines. In patient samples, IQSEC3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IQSEC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
